Show simple item record

dc.contributor.authorNikolaides, C.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorZoumbos, N.en
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorKarabelis, A.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorSymeonidis, A.en
dc.contributor.authorPapadopoulos, A.en
dc.contributor.authorAntoniou, F.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorNikolaides, C.en
dc.creatorFountzilas, Georgeen
dc.creatorZoumbos, N.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorPectasides, Dimitriosen
dc.creatorKarabelis, A.en
dc.creatorGiannakakis, T.en
dc.creatorSymeonidis, A.en
dc.creatorPapadopoulos, A.en
dc.creatorAntoniou, F.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:54:08Z
dc.date.available2018-06-22T09:54:08Z
dc.date.issued1998
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42209
dc.description.abstractSeveral clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently formulated. We tried to identify the clinical prognostic factors that predict treatment outcome in Greek patients with diffuse large cell lymphomas and validated the IPI in these patients. The possible prognostic variables for tumor response, relapse-free (RFS) and overall survival (OS) were analyzed in 239 consecutive patients treated with anthracycline-based chemotherapy regimens. In univariate analysis, factors associated with poor response were stages III-IV, performance status (PS) ≤ 2, spleen and bone marrow involvement, more than one extranodal site involved, increased lactate dehydrogenase (LDH) value, hemoglobin (Hb) 50 mm/h. Multivariate analysis identified stage, PS, more than one extranodal site involved, increased LDH level, and ESR > 50 mm/h as the factors more predictive of poor response. For RFS, multiple Cox analysis found stages III-IV and bone marrow involvement to be statistically significant. For OS, multiple Cox analysis identified stage III-IV, PS ≤ 2, bone marrow involvement, more than one extranodal site involved, increased LDH level and ESR > 50 mm/h as negative prognostic factors. Patients stratified in the different risk groups of the IPI had a significantly different outcome regarding complete response (CR) rate, RFS and OS. In conclusion, although age > 60 years was not recognized as an adverse factor in this analysis, our patients stratified in the different groups of the IPI had significant differences in CR rate, 2-year RFS and OS verifying the prognostic significance of the index. Bone marrow involvement and ESR > 50 mm/h, parameters that are not included in the IPI, adversely affected survival.en
dc.language.isoengen
dc.sourceOncologyen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectOncologyen
dc.subjectCancer survivalen
dc.subjectNeoplasm stagingen
dc.subjectPriority journalen
dc.subjectPrognosisen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectSurvival analysisen
dc.subjectMultivariate analysisen
dc.subjectNonhodgkin lymphomaen
dc.subjectMaleen
dc.subjectLogistic modelsen
dc.subjectDiffuseen
dc.subjectLarge cell lymphomaen
dc.subjectLarge-cellen
dc.subjectLymphomaen
dc.subjectPrognostic factorsen
dc.subjectLactate dehydrogenaseen
dc.subjectHuman cellen
dc.subjectSpleenen
dc.subjectGreeceen
dc.subjectInternational prognostic indexen
dc.subjectRemission inductionen
dc.subjectAnthracyclineen
dc.subjectBone marrowen
dc.subjectErythrocyte sedimentation rateen
dc.subjectBlood sedimentationen
dc.subjectCooperationen
dc.subjectDiffuse large cell lymphomaen
dc.subjectTreatment outcomeen
dc.titleDiffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Indexen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume55
dc.description.issue5
dc.description.startingpage405
dc.description.endingpage415
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record